Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allos Therapeutics, Inc.
Allos Therapeutics Announces Top Line Results from Pivotal Phase 2 PROPEL Trial of Pralatrexate in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
December 26th, 2008
Allos Therapeutics, Inc. (Nasdaq:ALTH) announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261). The results according to central independent oncology review at the time of this analysis are as follows: 29 of 109 evaluable patients (27%) achieved either a complete or partial response 11 evaluable patients had a complete response or complete response unconfirmed 18 evaluable patients had a partial response 23 evaluable patients had stable disease as best response 3...
Source: Health Business Week (2008-12-26)
|
